vimarsana.com
Home
Live Updates
Everest Medicines Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023 : vimarsana.com
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
/PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...
Related Keywords
Macau ,
Tokyo ,
Japan ,
Singapore ,
United Kingdom ,
United States ,
Shanghai ,
China ,
Stockholm ,
Sweden ,
South Korea ,
Taiwan ,
Hong Kong ,
Chinese ,
Rogers Yongqing Luo ,
European Union ,
International Symposium On Iga Nephropathy ,
Calliditas Therapeutics ,
Nasdaq Stockholm ,
International Symposium ,
Iga Nephropathy ,
Chief Executive Officer ,
Priority Review ,
Breakthrough Therapy Designation ,
Shanghai Ruijin Hospital ,
Everest Medicines ,
Mainland China ,
Everest Medicine ,
vimarsana.com © 2020. All Rights Reserved.